Abstract
Aging is a risk factor for several of the world's most prevalent diseases, including neurodegenerative disorders, cancer, cardiovascular disease and metabolic disease. Although our understanding of the molecular pathways that contribute to the aging process and age-related disease is progressing through the use of model organisms, how to apply this knowledge in the clinic is less clear. In September, Nature Medicine, in collaboration with the Volkswagen Foundation, hosted a conference at the beautiful Herrenhausen Palace in Hannover, Germany with the goal of broadening our understanding of the aging process and its meaning as a 'risk factor' in disease. Here, several of the speakers at that conference answer questions posed by Nature Medicine.
References
Longo, V.D. et al. Aging Cell 14, 497–510 (2015).
Fabbri, E. et al. J. Am. Med. Dir. Assoc. 16, 640–647 (2015).
Richardson, A. et al. J. Gerontol. A Biol. Sci. Med. Sci. (2015).
Monk, T.G. & Price, C.C. Curr. Opin. Crit. Care 17, 376–381 (2011).
The National Coalition for Cancer Survivorship. Pazdur: “The primary endpoint of every trial should be the patient.” The Cancer Letter http://www.cancerletter.com/articles/20151023_6 (23 October 2015)
Stanley, S.E. & Armanios, M. Curr. Opin. Genet. Dev. 33, 1–9 (2015).
Kennedy, B.K. et al. Cell 159, 709–713 (2014).
Burch, J.B. et al. J. Gerontol. A Biol. Sci. Med. Sci. 69 Suppl 1, S1–S3 (2014).
Fontana, L. et al. Nature 511, 405–407 (2014).
Sperling, R.A., Jack, C.R., Jr. & Aisen, P.S. Sci. Transl. Med. 3, 111cm133 (2011).
Avorn, J. & Kesselheim, A.S. N. Engl. J. Med. 372, 2473–2475 (2015).
Doody, R.S. et al. N. Engl. J. Med. 370, 311–321 (2014).
Belsky, D.W. et al. Proc. Natl. Acad. Sci. USA 112, E4104–E4110 (2015).
Verghese, J. et al. J. Neurol. Neurosurg. Psychiatry 78, 929–935 (2007).
Kaeberlein, M. Vet Pathol. doi:10.1177/0300985815591082 (15 June 2015).
Fontana, L. et al. Am. J. Physiol. Endocrinol. Metab. 293, E197–E202 (2007).
Brunner, S., Herndler-Brandstetter, D., Weinberger, B. & Grubeck-Loebenstein, B. Ageing Res. Rev. 10, 362–369 (2011).
Friedman, D.B. & Johnson, T.E. Genetics 118, 75–86 (1988).
de Cabo, R., Carmona-Gutierrez, D., Bernier, M., Hall, M.N. & Madeo, F. Cell 157, 1515–1526 (2014).
Ingram, D.K. et al. Aging Cell 5, 97–108 (2006).
Madeo, F., Pietrocola, F., Eisenberg, T. & Kroemer, G. Nat. Rev. Drug Discov. 13, 727–740 (2014).
Jonker, M.J. et al. Aging Cell 12, 901–909 (2013).
Liao, C.Y., Rikke, B.A., Johnson, T.E., Diaz, V. & Nelson, J.F. Aging Cell 9, 92–95 (2010).
Mannick J.B. et al. Sci. Transl. Med. 24, 268ra179 (2014).
Sadagurski, M. et al. Am. J. Physiol. Endocrinol. Metab. 306, E1305–E1314 (2014).
Villeda, S.A. et al. Nature 477, 90–94 (2011).
Katsimpardi, L. et al. Science 344, 630–634 (2014).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J.M. declares an equity interest in Novartis. All other authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Armanios, M., de Cabo, R., Mannick, J. et al. Translational strategies in aging and age-related disease. Nat Med 21, 1395–1399 (2015). https://doi.org/10.1038/nm.4004
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4004
- Springer Nature America, Inc.
This article is cited by
-
A risk stratification and prognostic prediction model for lung adenocarcinoma based on aging-related lncRNA
Scientific Reports (2023)
-
Repurposed FDA-approved drugs targeting genes influencing aging can extend lifespan and healthspan in rotifers
Biogerontology (2018)
-
Repurposing FDA-approved drugs for anti-aging therapies
Biogerontology (2016)